L P Andersen

Statens Serum Institut, København, Capital Region, Denmark

Are you L P Andersen?

Claim your profile

Publications (136)527.18 Total impact

  • Anna Walduck · Leif P Andersen · Sukanya Raghavan
    [Show abstract] [Hide abstract]
    ABSTRACT: During the last year, a variety of studies have been published that increases our understanding of the basic mechanisms of immunity and inflammation in Helicobacter pylori infection and progression to gastric cancer. Innate immune regulation and epithelial cell response were covered by several studies that contribute with new insights in the host response to H. pylori infection. Also, the adaptive immune response to H. pylori and particularly the role of IL-22 have been addressed in some studies. These advances may improve vaccine development where new strategies have been published. Two major studies analyzed H. pylori genomes of 39 worldwide strains and looked at the protein profiles. In addition, multi-epitope vaccines for therapeutic use have been investigated. Studies on different adjuvants and delivery systems have also given us new insights. This review presents articles from the last year that reveal detailed insight into immunity and regulation of inflammation, the contribution of immune cells to the development of gastric cancer, and understanding mechanisms of vaccine-induced protection.
    No preview · Article · Sep 2015 · Helicobacter
  • Leif Percival Andersen · Xiaohui Nielsen
    [Show abstract] [Hide abstract]
    ABSTRACT: Even though methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of nosocomial infections, it may often be difficult to evaluate the exact route of transmission. In this study, we describe four cases of nosocomial transmission of MRSA in a hospital with a low MRSA incidence. In one case, a multi-traumatic patient arrived from a hospital in a foreign country and the primary surveillance swaps were negative for MRSA. The second case was a child with burn wounds who was referred from a Danish hospital. The third case was a multi-traumatic patient from Denmark. The fourth case was a new-born child in the neonate unit. In none of the cases, the index patient was known to have MRSA on admission and no specific precautions were taken to prevent transmission. In all cases there was intensive contact between the patient and the staff which may increase the risk of contaminating hands, arms and the front of the uniform. Hand hygiene is therefore essential, but the use of protection gowns with long sleeves is also important in order to prevent transmission of MRSA. After culture of MRSA and implementation of specific precautions to prevent transmission of MRSA, no further transmissions were observed. not relevant. The data in this study are included in the routine surveillance of MRSA at Rigshospitalet and do not form part of a trial.
    No preview · Article · Apr 2015 · Danish Medical Journal
  • Source

    Full-text · Dataset · Mar 2015
  • Source

    Full-text · Dataset · Mar 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Reducing adhesion of Helicobacter pylori to gastric epithelial cells could be a new way to counteract infections with this organism. We here present a novel method for quantification of Helicobacter pylori adhesion to cells. Helicobacter pylori is allowed to adhere to AGS or MKN45g cells in a 96-well microtiter plate. Then wells are added saponin, which lyses the cells without affecting the bacteria. After addition of alamarBlue(®) (resazurin) and 1- to 2-hour incubation, fluorescence measurements can be used to quantify the number of adherent bacteria. By use of the method, we demonstrate that adhesion of both a sabA and babA deletion mutant of H. pylori is significantly reduced compared to the wild type. The method offers a number of applications and may be used to compare the adherence potential of different strains of H. pylori to either cells or different materials or to screen for potential anti-adhesive compounds. The results presented here suggest that this easy and reproducible assay is well suited for quantitative investigation of H. pylori adhesion. © 2015 John Wiley & Sons Ltd.
    Full-text · Article · Jan 2015 · Helicobacter
  • Source

    Full-text · Dataset · May 2014
  • Source
    LP Andersen · A-MB Hellesoe · B Rubenhagen · M Høg

    Preview · Article · Jun 2013
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The emergence of extreme-drug-resistant (EDR) bacterial strains in hospital and nonhospital clinical settings is a big and growing public health threat. Understanding the antibiotic resistance mechanisms at the genomic levels can facilitate the development of next-generation agents. Here, comparative genomics has been employed to analyze the rapid evolution of an EDR Acinetobacter baumannii clone from the intensive care unit (ICU) of Rigshospitalet at Copenhagen. Two resistant A. baumannii strains, 48055 and 53264, were sequentially isolated from two individuals who had been admitted to ICU within a 1-month interval. Multilocus sequence typing indicates that these two isolates belonged to ST208. The A. baumannii 53264 strain gained colistin resistance compared with the 48055 strain and became an EDR strain. Genome sequencing indicates that A. baumannii 53264 and 48055 have almost identical genomes—61 single-nucleotide polymorphisms (SNPs) were found between them. The A. baumannii 53264 strain was assembled into 130 contigs, with a total length of 3,976,592 bp with 38.93% GC content. The A. baumannii 48055 strain was assembled into 135 contigs, with a total length of 4,049,562 bp with 39.00% GC content. Genome comparisons showed that this A. baumannii clone is classified as an International clone II strain and has 94% synteny with the A. baumannii ACICU strain. The ResFinder server identified a total of 14 antibiotic resistance genes in the A. baumannii clone. Proteomic analyses revealed that a putative porin protein was down-regulated when A. baumannii 53264 was exposed to antimicrobials, which may reduce the entry of antibiotics into the bacterial cell.
    Full-text · Article · Mar 2013 · Genome Biology and Evolution
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Resistance to antibiotics is the major cause of treatment failure of Helicobacter pylori infection. A study was conducted to assess prospectively the antibacterial resistance rates of H pylori in Europe and to study the link between outpatient antibiotic use and resistance levels in different countries. Design: Primary antibiotic resistance rates of H pylori were determined from April 2008 to June 2009 in 18 European countries. Data on yearly and cumulative use over several years of systemic antibacterial agents in ambulatory care for the period 2001-8 were expressed in Defined Daily Doses (DDD) per 1000 inhabitants per day. The fit of models and the degree of ecological association between antibiotic use and resistance data were assessed using generalised linear mixed models. Results: Of 2204 patients included, H pylori resistance rates for adults were 17.5% for clarithromycin, 14.1% for levofloxacin and 34.9% for metronidazole, and were significantly higher for clarithromycin and levofloxacin in Western/Central and Southern Europe (>20%) than in Northern European countries (<10%). Model fit improved for each additional year of antibiotic use accumulated, but the best fit was obtained for 2005. A significant association was found between outpatient quinolone use and the proportion of levofloxacin resistance (p=0.0013) and between the use of long-acting macrolides only and clarithromycin resistance (p=0.036). Conclusion: In many countries the high rate of clarithromycin resistance no longer allows its empirical use in standard anti-H pylori regimens. The knowledge of outpatient antibiotic consumption may provide a simple tool to predict the susceptibility of H pylori to quinolones and to macrolides and to adapt the treatment strategies.
    No preview · Article · Jan 2013 · Gut
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: Resistance to antibiotics is the major cause of treatment failure of Helicobacter pylori infection. A study was conducted to assess prospectively the antibacterial resistance rates of H pylori in Europe and to study the link between outpatient antibiotic use and resistance levels in different countries. DESIGN: Primary antibiotic resistance rates of H pylori were determined from April 2008 to June 2009 in 18 European countries. Data on yearly and cumulative use over several years of systemic antibacterial agents in ambulatory care for the period 2001-8 were expressed in Defined Daily Doses (DDD) per 1000 inhabitants per day. The fit of models and the degree of ecological association between antibiotic use and resistance data were assessed using generalised linear mixed models. RESULTS: Of 2204 patients included, H pylori resistance rates for adults were 17.5% for clarithromycin, 14.1% for levofloxacin and 34.9% for metronidazole, and were significantly higher for clarithromycin and levofloxacin in Western/Central and Southern Europe (>20%) than in Northern European countries (<10%). Model fit improved for each additional year of antibiotic use accumulated, but the best fit was obtained for 2005. A significant association was found between outpatient quinolone use and the proportion of levofloxacin resistance (p=0.0013) and between the use of long-acting macrolides only and clarithromycin resistance (p=0.036). CONCLUSION: In many countries the high rate of clarithromycin resistance no longer allows its empirical use in standard anti-H pylori regimens. The knowledge of outpatient antibiotic consumption may provide a simple tool to predict the susceptibility of H pylori to quinolones and to macrolides and to adapt the treatment strategies.
    Full-text · Article · Jan 2013 · Gut
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We conducted a retrospective epidemiologic study of catheter related bloodstream infections (CRBSI) in patients receiving long-term home parenteral nutrition (HPN) from January 2002 to December 2005. Our results showed that coagulase negative staphylococci (CoNS) were the most prevalent pathogens (44.7% of all CRBSI episodes), followed by Enterobacteriaceae (33.2%). Prevalence for candidemia and Enterococcus bacteremia was relatively high (14.4% and 10.8%, respectively). Cefuroxime resistance was observed in 65.4% CoNS and 31.5% Enterobacteriaceae. Based on the results from the study, a new empiric antimicrobial treatment regiment was suggested.
    Full-text · Article · Nov 2012 · The Open Microbiology Journal
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The study evaluated the changes in the prevalence of Helicobacter pylori strains with primary resistance to antibiotics during the last 10 years in Lithuania. H. pylori susceptibilities to antibiotics were tested in 89 patients in 1998, in 81 patients in 2001 and in 90 patients in 2007/2008. Susceptibility to metronidazole, clarithromycin, amoxicillin and tetracycline was tested using E-test or agar dilution method. Susceptibility to ciprofloxacin was only tested in 2007/2008. Data about utilization of all authorized and available on market macrolides and clindamycin in Lithuania during 2003-2007 were evaluated using WHO ATC/DDD methodology. A total of 260 H. pylori strains cultured from untreated adult patients were investigated. Primary resistance rates (1998, 2001 and 2007/2008) for metronidazole were 24.7%, 33.3%, and 35.6%, for clarithromycin 1.1%, 3.7%, and 3.3% and for tetracycline 0%, 2.5% and 0% respectively. No cases of amoxicillin resistance have been detected. The resistance rate for ciprofloxacin was 5.6% in 2007/2008. Data of total macrolides and clarithromycin utilization in Lithuania revealed that despite an increase of consumption of these drugs in Lithuania during 2003-2007 in 1.5 times, the total macrolide consumption remains one of the lowest in Europe. We have not observed any significant changes in the susceptibility of H. pylori to the most widely used antibiotics during the recent 10-year period. The low resistance rate to clarithromycin might be related to the policy to avoid use of macrolides as first-line treatment for pulmonary and other infections.
    Full-text · Article · Oct 2012 · Apmis

  • No preview · Article · Jan 2011 · Gastroenterology
  • Lone Rasmussen · Leif Percival Andersen
    [Show abstract] [Hide abstract]
    ABSTRACT: Helicobacter pylori is a Gram-negative, microaerophilic curved rod, that possesses an unipolar bundle of two to six flagella which enables it to move to a specific target with high concentration of chemoattractants, such as urea. H. pylori is a pathogenic bacterium, which is present in more than half of the population worldwide with a range from 20 to 30% in developed countries to 60–80% in developing countries.
    No preview · Chapter · Oct 2010
  • Source
    M Suppli · R Aabenhus · Z B Harboe · L P Andersen · M Tvede · J-U S Jensen
    [Show abstract] [Hide abstract]
    ABSTRACT: Enterococcus species are common in nosocomial bloodstream infections and their incidence is rising. Although well recognized in several serious bacterial infections, the influence of appropriate antimicrobial therapy in enterococcal bacteraemia has not been fully settled. The aim of the study was to determine whether administration of inappropriate antibiotics in enterococcal bacteraemia is an independent risk factor for mortality, among other known and suspected risk factors. We conducted a cohort study of E. faecalis/faecium bacteraemia during a 3-year period at a single tertiary care hospital in Denmark. Patients with growth of non-enterococcus co-pathogens apart from the enterococcal bacteraemia were also included, as were patients with repeated enterococcal bacteraemia. Time to appropriate antimicrobial therapy was counted from the first episode. Appropriate antibiotic therapy was defined as any therapy with documented clinical effect, in vitro activity and a minimum treatment length of 6 days. Multivariate regression models were built to determine the independent risk factors for mortality. We included 196 patients with enterococcal bacteraemia. Appropriate antibiotics for at least 6 days were administered in 146 of these (74%). Thirty-day mortality was 26%. Multivariate logistic regression identified independent predictors of 30-day all-cause mortality: appropriate antimicrobial therapy for ≥ 6 days (odds ratio for mortality 0.33, 0.14-0.79), ICU admission (4.2, 1.7-10), thrombocytopenia (3.9, 1.6-9.3), chronic liver failure (3.3, 1.1-10) and age ≥ 60 years (2.2, 0.99-5.0). Antibiotics not appropriately covering enterococci are frequently administered empirically in suspected bloodstream infections. Inappropriate antibiotic therapy was an independent risk factor for mortality in enterococcal bacteraemia.
    Full-text · Article · Oct 2010 · Clinical Microbiology and Infection
  • L P Andersen · P Lange · M Tvede

    No preview · Article · Jul 2010 · European Journal of Clinical Microbiology
  • Jalal Alimoradi · Lone Rasmussen · Leif Percival Andersen
    [Show abstract] [Hide abstract]
    ABSTRACT: Helicobacter pylori (H. pylori) is recognized as the causative of several gastroduodenal disorders. The discovery of H. pylori revolutionized the treatment for ulcus pepticum. Antibiotics combined with proton pump inhibitors or bismuth have been effective in the treatment of H. pylori infections, but there is an emerging problem with H. pylori resistance against the most frequently used antibiotics, which substantially impairs the treatment of H. pylori-associated disorders. In this article the focus is on the prevalence of H. pylori resistance, its clinical implications and the molecular mechanisms behind resistance development.
    No preview · Article · May 2010 · Ugeskrift for laeger
  • L. P. Andersen · P. Lange · M. Tvede

    No preview · Article · Apr 2010
  • [Show abstract] [Hide abstract]
    ABSTRACT: Heat-stable antigens from Helicobacter pylori were investigated for the detection of serum IgG, IgA and IgM antibodies against H. pylori by an ELISA technique. Antibody titers against H. pylori were measured in 167 dyspeptic patients, of whom 96 were H. pylori positive confirmed by culture or microscopy, and in 482 controls (0–98 years). Increased IgG antibody titers were found significantly more often in dyspeptic patients with active chronic gastritis than in patients with normal morphology, as well as in H. pylori-positive patients as compared to H. pylori-negative patients, independent of the endoscopic findings. The heat-stable antigens were compared with acid glycine-extracted antigens and a high degree of concordance was found in the results obtained with the two antigen preparations. The differences in the IgA antibody titers against H. pylori between H. pylori-positive and H. pylori-negative dyspeptic patients were significant and may be useful to confirm a borderline IgG result. No differences were found in IgM antibody titer between H. pylori-positive and -negative patients. The greatest age-dependent increase in IgG and IgA antibody titers was found in children, and if a lower cut-off level is used for children than for adults, as has been proposed, the proportion of people with increased antibody titers against H. pylori would be almost constant from the age of between five and 10 years until the time between 61 and 80 years. Comparison of H. pylori IgG antibodies with IgG antibodies against Campylobacter jejuni and total antibodies against cytomegalovirus (CMV) showed a greater similarity between H. pylori and C. jejuni (R = 0.51) than between H. pylori and CMV (R = 0.22). This may possibly be caused by cross-reactions between H. pylori and C. jejuni. The H. pylori heat-stabile antigen seems not to be very different from other crude H. pylori antigens like acid glycine-extracted antigens, but purification and characterization of the antigens are needed to improve antibody assays.
    No preview · Article · Aug 2009 · Apmis
  • Source
    Leif Percival Andersen · Lone Rasmussen
    [Show abstract] [Hide abstract]
    ABSTRACT: Electron microscopic studies have shown that Helicobacter pylori occurs in three stages: spiral forms, coccoid forms and degenerative forms. The spiral forms are viable, culturable, virulent and can colonize experimental animals and induce inflammation. The coccoid forms may also be viable but are nonculturable, less virulent and are less likely to colonize and induce inflammation in experimental animals than the spiral forms. The degenerative forms are pyknotic, nonculturable, coccoid forms of dead H. pylori. These forms cannot be cultured and the cell membrane has disintegrated but gene material can be detected by PCR in water supplies. There is no substantial evidence for viable H. pylori persisting in water supplies. Epidemiological studies suggest that environmental water is a risk factor for H. pylori infection when compared with tap water, and formation of H. pylori biofilm cannot be excluded. Helicobacter pylori does not seem to take part in biofilm formation in the oral cavity even though the bacterium may be detected.
    Preview · Article · May 2009 · FEMS Immunology & Medical Microbiology

Publication Stats

4k Citations
527.18 Total Impact Points

Institutions

  • 2015
    • Statens Serum Institut
      • Department of Microbiology and Infection Control
      København, Capital Region, Denmark
  • 1993-2015
    • IT University of Copenhagen
      København, Capital Region, Denmark
  • 1995-2013
    • Copenhagen University Hospital
      København, Capital Region, Denmark
  • 1998-2010
    • Glostrup Hospital
      Glostrup, Capital Region, Denmark
    • Frederiksberg Hospital
      Фредериксберг, Capital Region, Denmark
  • 1999-2008
    • Rigshospitalet
      • Department of Clinical Microbiology
      København, Capital Region, Denmark
  • 2005
    • Erasmus MC
      • Department of Gastroenterology and Hepatology
      Rotterdam, South Holland, Netherlands
  • 2001-2005
    • National University (California)
      San Diego, California, United States
    • Bispebjerg Hospital, Copenhagen University
      København, Capital Region, Denmark
  • 2002
    • Lund University
      Lund, Skåne, Sweden
  • 1989-1995
    • Hillerød Hospital
      Hillerød, Capital Region, Denmark
  • 1994
    • Copenhagen University Hospital Hvidovre
      Hvidovre, Capital Region, Denmark
  • 1987
    • Central Peninsula Hospital
      SXQ, Alaska, United States